RECRUITING

Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (TGD) youth compared to cis-gender youth. Limited existing literature demonstrates the need for contraceptive counseling that moves beyond cis- and heteronormative assumptions that start with pregnancy prevention and address concerns at the intersection of gender identity. The Investigator's qualitative study will focus on creating best practices regarding equitable contraceptive counseling for TGD youth. The Investigator will recruit transgender youth who are assigned female at birth, and currently or interested in using depo medroxyprogesterone (DMPA). Through focus groups and semi-structured interviews, the investigator hopes to guide providers in creating best practices and more equitable contraceptive counseling for TGD youth and measure satisfaction of DMPA in TGD youth.

Official Title

Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone

Quick Facts

Study Start:2022-12-06
Study Completion:2027-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05726903

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:15 Years to 21 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * between the ages of 15-21,
  2. * currently receiving care at one of the clinic sites, assigned female at birth, identify as transgender or gender diverse , and are currently using or are interested in using DMPA.
  1. * Any contraindications to DMPA (based on any category 3 or 4 recommendations from the CDC MEC guidelines)

Contacts and Locations

Study Contact

Nancy Z Fang, MD
CONTACT
3037248482
NANCY.FANG@CUANSCHUTZ.EDU
Eva M Dindinger, MPH
CONTACT
303-724-8482
Eva.Dindinger@CUAnschutz.edu

Principal Investigator

Eva M Dindinger, MPH
STUDY_CHAIR
University of Colorado, Denver

Study Locations (Sites)

Comprehensive Women's Health Center
Denver, Colorado, 80230
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Eva M Dindinger, MPH, STUDY_CHAIR, University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-06
Study Completion Date2027-06-01

Study Record Updates

Study Start Date2022-12-06
Study Completion Date2027-06-01

Terms related to this study

Additional Relevant MeSH Terms

  • Gender Dysphoria, Adolescent